A Multicenter Randomized Clinical Phase 3 Trial of Induction Chemotherapy Plus Concurrent Chemo-radiotherapy With or Without Camrelizumab for High Risk Nasopharyngeal Carcinoma
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 24 Sep 2020 Planned End Date changed from 1 Jul 2028 to 1 Sep 2028.
- 24 Sep 2020 Planned primary completion date changed from 1 Jul 2026 to 1 Sep 2026.
- 24 Sep 2020 Status changed from not yet recruiting to recruiting.